5/17
08:17 am
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Mizuho from $9.00 to $3.00. They now have a "buy" rating on the stock.
Medium
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Mizuho from $9.00 to $3.00. They now have a "buy" rating on the stock.
5/15
07:49 am
adap
Adaptimmune GAAP EPS of -$0.03 beats by $0.04, revenue of $5.7M misses by $11.37M [Seeking Alpha]
Medium
Report
Adaptimmune GAAP EPS of -$0.03 beats by $0.04, revenue of $5.7M misses by $11.37M [Seeking Alpha]
5/15
07:49 am
adap
Adaptimmune Reports Q1 2024 Financial and Business Updates [Yahoo! Finance]
Medium
Report
Adaptimmune Reports Q1 2024 Financial and Business Updates [Yahoo! Finance]
5/15
07:12 am
adap
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital [Yahoo! Finance]
High
Report
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital [Yahoo! Finance]
5/1
12:11 pm
adap
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 [Yahoo! Finance]
Low
Report
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 [Yahoo! Finance]
4/29
07:39 am
adap
Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase [Yahoo! Finance]
Medium
Report
Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase [Yahoo! Finance]
4/26
11:10 am
adap
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech [Seeking Alpha]
Low
Report
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech [Seeking Alpha]
4/23
07:53 am
adap
Garry Menzel joins GHO Capital as Operating Partner [Yahoo! Finance]
Medium
Report
Garry Menzel joins GHO Capital as Operating Partner [Yahoo! Finance]
4/15
04:02 pm
adap
Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]
Medium
Report
Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]
4/12
08:57 am
adap
Adaptimmune falls as Roche strategic collaboration ends [Seeking Alpha]
Medium
Report
Adaptimmune falls as Roche strategic collaboration ends [Seeking Alpha]
4/12
08:14 am
adap
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated [Yahoo! Finance]
Medium
Report
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated [Yahoo! Finance]
3/27
07:35 pm
adap
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet [Yahoo! Finance]
Neutral
Report
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet [Yahoo! Finance]
3/8
05:32 am
adap
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Low
Report
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
3/7
01:53 pm
adap
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
3/7
08:41 am
adap
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/6
07:12 am
adap
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
High
Report
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
2/27
08:17 am
adap
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise [Yahoo! Finance]
Medium
Report
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise [Yahoo! Finance]